Humanigen Reports Third Quarter 2022 Financial Results Nov 14, 2022 04:01PM
Humanigen Announces Participation and Presentation at Jefferies London Healthcare Conference Nov 10, 2022 08:02AM
Humanigen Announces Retention of SC&H Capital as Financial Advisor Oct 31, 2022 08:01AM
Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors Sep 1, 2022 07:00AM
Humanigen Inc. (HGEN) Reports Q2 EPS of ($0.43) Aug 12, 2022 04:02PM
View Older Stories

Aug 12, 2022 04:00PM Humanigen Reports Second Quarter 2022 Financial Results
Jul 26, 2022 07:32AM Humanigen Inc. (HGEN) Announces Strategic Realignment of Pipeline and Resources to Achieve Key Clinical Milestones
Jul 26, 2022 07:30AM Humanigen Implements Strategic Realignment of Pipeline and Resources to Achieve Key Clinical Milestones
Jul 13, 2022 05:51AM Humanigen (HGEN) Reports Preliminary Topline Data From NIH/NIAID Study of Lenzilumab in ACTIV-5/BET-B
Jul 12, 2022 08:30PM Humanigen Receives Preliminary Topline Data From NIH/NIAID Study of Lenzilumab in ACTIV-5/BET-B
Jul 6, 2022 08:08AM Humanigen Inc. (HGEN) Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by C-Reactive Protein
Jul 6, 2022 08:00AM Humanigen Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by C-Reactive Protein
Jul 6, 2022 08:00AM Humanigen Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by C-Reactive Protein
Jun 30, 2022 08:19AM Humanigen Inc. (HGEN) Announces NIH/NIAID Lock of ACTIV-5/BET-B Database, On Track for Results in July
Jun 30, 2022 08:19AM NIH/NIAID Locks ACTIV-5/BET-B Database
Jun 16, 2022 06:31AM Humanigen Inc. (HGEN) Enters Agreement with PCI Pharma Services as Part of Preparations for Commercialization in the UK
Jun 16, 2022 06:30AM Humanigen Enters into Agreement with PCI Pharma Services as Part of Preparations for Commercialization in the United Kingdom
Jun 3, 2022 07:00AM Humanigen Announces Participation and Presentation at Multiple Conferences in June
May 24, 2022 06:30AM Humanigen Announces Participation and Presentation at H.C. Wainwright Global Investment Conference
May 5, 2022 04:00PM Humanigen Reports First Quarter 2022 Financial Results
May 4, 2022 07:00AM Humanigen Announces Participation and Presentation at Multiple Conferences in May
Apr 20, 2022 06:32AM Humanigen Inc. (HGEN) Announces Publication of GM-CSF Knock-out CAR-T Study
Apr 20, 2022 06:30AM GM-CSF Knock-out CAR-T Study Published in Peer-Reviewed Journal Leukemia
Apr 19, 2022 06:32AM Humanigen, Inc. (HGEN) Reports Peer-Reviewed Publication Demonstrating the Potential Clinical and Economic Benefits of Lenzilumab
Apr 19, 2022 06:30AM Humanigen Announces Peer-Reviewed Publication Demonstrating the Potential Clinical and Economic Benefits of Lenzilumab from the Perspective of the NHS
Feb 28, 2022 01:05PM Humanigen Reports Year-End 2021 Financial Results
Feb 25, 2022 05:55AM Humanigen to Present and Participate at Multiple Investor Events in March
Feb 11, 2022 05:55AM Humanigen to Present at BIO CEO & Investor Conference
Feb 10, 2022 04:44AM Humanigen Inc. (HGEN) Launches Managed Access Program for Lenzilumab
Feb 9, 2022 11:55PM Humanigen Launches Managed Access Program for Lenzilumab
Feb 9, 2022 04:11AM Humanigen Inc. (HGEN) Collaborates with Cenexi to Manufacture Lenzilumab in France
Feb 8, 2022 11:55PM Humanigen and Cenexi Announce Collaboration to Manufacture Lenzilumab in France
Jan 18, 2022 05:59AM Humanigen Inc. (HGEN) Reports Peer-Reviewed Publication Demonstrating the Clinical and Economic Benefits of Lenzilumab
Jan 18, 2022 05:55AM Humanigen Announces Peer-Reviewed Publication in The Journal of Medical Economics Demonstrating the Clinical and Economic Benefits of Lenzilumab
Jan 10, 2022 05:58AM Humanigen Inc. (HGEN) Agrees with FDA on Terms of Potential Registration Phase 3 Study for Lenzilumab with CAR-T
Jan 10, 2022 05:55AM Humanigen Aligns with FDA on Potential Registration Phase 3 Study for Lenzilumab with CAR-T
Jan 5, 2022 06:05AM Humanigen Announces Target Enrollment in Phase 2/3 ACTIV-5/BET-B Trial of Lenzilumab for the Treatment of COVID-19 has Been Achieved
Jan 4, 2022 05:55AM Humanigen to Present at Investor Conferences January 7 and 13, 2022
Jan 3, 2022 05:58AM Humanigen Inc. (HGEN) Reports Lenzilumab Treatment Response in Hospitalized COVID-19 Patients Correlates with C-Reactive Protein Levels
Jan 3, 2022 05:55AM Lenzilumab Treatment Response in Hospitalized COVID-19 Patients Correlates with C-Reactive Protein Levels
Dec 15, 2021 08:59AM Humanigen Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference in January 2022
Dec 1, 2021 06:45PM Humanigen Announces Conference Call and Webcast to Discuss Lancet Respiratory Medicine Publications and Provide a Corporate Update
Dec 1, 2021 06:30PM The Lancet Respiratory Medicine Publishes Peer-Reviewed Paper and Independent Expert Commentary on Positive Phase 3 Lenzilumab Results
Nov 22, 2021 06:30AM Humanigen Announces Abstracts Accepted for the British Thoracic Society Winter Meeting 2021
Nov 16, 2021 07:47AM Humanigen Announces Revised Time for Presentation at Jefferies London Healthcare Conference
Nov 12, 2021 04:00PM Humanigen Reports Third Quarter and Nine Months Ending September 30, 2021 Financial Results and Provides Corporate Update
Nov 11, 2021 06:33AM Humanigen Inc. (HGEN) Enters Clinical Collaboration to Evaluate Lenzilumab in Acute Graft Versus Host Disease
Nov 11, 2021 06:30AM Humanigen Announces Clinical Trial Collaboration to Evaluate Lenzilumab in Acute Graft Versus Host Disease
Nov 5, 2021 10:34AM Humanigen Announces Release of Abstracts at ASH
Nov 2, 2021 08:30AM Humanigen Announces Participation and Presentation at Multiple Conferences in November
Oct 26, 2021 06:30AM First Patient Dosed in Phase 2 Precision Medicine Study of Lenzilumab in Patients with Chronic Myelomonocytic Leukemia (CMML)
Oct 25, 2021 10:34AM Humanigen Inc's (HGEN) Lenzilumab Selected by EU as One of 10 Most Promising COVID-19 Treatments
Oct 25, 2021 10:30AM European Commission Selects Humanigen’s Lenzilumab as One of the 10 Most Promising Treatments for COVID-19
Oct 25, 2021 10:30AM European Commission Selects Humanigen’s Lenzilumab as One of the 10 Most Promising Treatments for COVID-19
Oct 22, 2021 07:00AM Humanigen announces preparation of Phase 1b study of ifabotuzumab in solid tumors following presentation of Phase 1 study results at EANM‘21
View Older Stories